文献速递炎症性肠病消化道肿瘤与早癌

炎症性肠病与非炎症性肠病患者结肠癌术后结局:一项全国队列研究

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-07-22

基于全国结直肠癌数据库纳入2007—2021年接受根治性手术的I—III期结肠癌患者35640例,其中675例(1.9%)合并炎症性肠病。调整混杂因素后,合并炎症性肠病患者的总体生存(HR=1.38)、无复发生存(HR=1.33)和癌症特异性生存(HR=1.46)均劣于无炎症性肠病患者。

要点

  • 合并炎症性肠病的结肠癌患者术后总体生存、无复发生存和癌症特异性生存均更差。
  • 炎症性肠病患者中仅少数(10%)行全直肠结肠切除术,61%行肠段切除术。
  • 合并炎症性肠病的结肠癌患者诊断时中位年龄为68岁,无炎症性肠病者为75岁。

核心结论

  • 炎症性肠病对结肠癌预后产生负面影响,合并炎症性肠病的结肠癌患者结局需要改善。

研究设计与样本

  • 利用全国结直肠癌数据库开展的队列研究,纳入2007—2021年接受根治性治疗的I—III期、年龄≥15岁的结肠癌患者,共35640例,其中675例(1.9%)合并炎症性肠病。

主要发现

  • 合并炎症性肠病患者结肠癌诊断时中位年龄为68岁,无炎症性肠病者为75岁;男性比例分别为55%和49%。
  • 合并炎症性肠病患者中,全直肠结肠切除术占10%,结肠次全切除术占29%,肠段切除术占61%。
  • 调整性别、年龄、结肠癌手术日期、Charlson合并症指数和原发性硬化性胆管炎后,合并炎症性肠病患者总体生存较无炎症性肠病者更差(HR=1.38;95%CI:1.21-1.57)。
  • 合并炎症性肠病患者无复发生存较无炎症性肠病者更差(HR=1.33;95%CI:1.18-1.50)。
  • 合并炎症性肠病患者癌症特异性生存较无炎症性肠病者更差(HR=1.46;95%CI:1.23-1.73)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To estimate the impact of inflammatory bowel disease on survival in a national cohort of patients following surgical resection for colon cancer, and to describe the surgical treatment of colon cancer in patients with inflammatory bowel disease. METHODS: Using the Colorectal Cancer Database, we included all patients ≥ 15 years of age with a diagnosis of stages I-III colon cancer treated with curative intent 2007-2021. We used Cox proportional hazards models to compare overall survival, recurrence-free survival and cancer-specific survival between patients with and without inflammatory bowel disease. Multivariable analyses were adjusted for sex, age, date of colon cancer surgery, Charlson Comorbidity Index and primary sclerosing cholangitis. RESULTS: Among 35,640 patients with colon cancer, 675 (1.9%) had inflammatory bowel disease. Median age at colon cancer diagnosis was 68 years in patients with inflammatory bowel disease and 75 in those without; proportions of male sex were 55% and 49%, respectively. In patients with inflammatory bowel disease, surgical therapy was proctocolectomy in 10%, subtotal colectomy in 29% and segmental resection in 61%. From adjusted analyses, patients with inflammatory bowel disease had worse overall survival (HR = 1.38; 95% CI: 1.21-1.57), recurrence-free survival (HR = 1.33; 95% CI: 1.18-1.50) and cancer-specific survival (HR = 1.46; 95% CI: 1.23-1.73) than patients without. CONCLUSION: Inflammatory bowel disease negatively influences the prognosis of colon cancer. Proctocolectomy was performed only in a minority of those with inflammatory bowel disease. Outcomes need to be improved in patients with inflammatory bowel disease developing colon cancer.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lundqvist E, Westberg K, Boman SE, et al. Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 40696766. doi:10.1111/apt.70296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。